Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
TFPI encodes a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. De plus, nous expédions TFPI Anticorps (187) et TFPI Protéines (32) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 89 products:
Mouse (Murine) TFPI Kit ELISA pour Sandwich ELISA - ABIN415387
Walter, Steinwede, Aly, Reinheckel, Bohling, Maus, Ehlers: Cathepsin G in Experimental Tuberculosis: Relevance for Antibacterial Protection and Potential for Immunotherapy. dans Journal of immunology (Baltimore, Md. : 1950) 2015
Show all 3 Pubmed References
Human TFPI Kit ELISA pour Sandwich ELISA - ABIN416737
Farid, Mohammed, Afifi, Beltagi: Tissue factor pathway inhibitor in paediatric patients with nephrotic syndrome. dans SAJCH : the South African journal of child health 2012
Human TFPI Kit ELISA pour Sandwich ELISA - ABIN1672813
Xu, Qin, Zhou, Tu, Bi, Li, Fan, Zhang: Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma. dans Oncology letters 2012
TFPI-1 interacts with AMOT (Montrer AMOT Kits ELISA), which led to a decrease in the phosphorylation of YAP (Montrer YAP1 Kits ELISA) and further increased the genes expression of the proliferation and migration involved. Our results further confirmed that atherosclerosis was a localized disease.
Results suggest that endothelial cell-anchored TFPI controls lung tumor metastasis, and does so largely through the inhibition of local TF-induced thrombin (Montrer F2 Kits ELISA) generation and the regulation of the lung microenvironment in mice.
Data argue against an important role for endogenous TFPI in the antibacterial, inflammatory and procoagulant response during pneumococcal pneumonia.
TFPI has an anti-proliferative role in TNF-alpha (Montrer TNF Kits ELISA) stimulated-VSMCs at least partly by interfering with the MCP-3 (Montrer CCL7 Kits ELISA)/CCR2 (Montrer CCR2 Kits ELISA) pathway and then via suppression of the ERK1/2 (Montrer MAPK1/3 Kits ELISA) and PI3K/AKT (Montrer AKT1 Kits ELISA) signaling pathways
Results demonstrate that TFPI physiologically modulates thrombin (Montrer F2 Kits ELISA)-dependent platelet activation in a manner that is required for successful embryonic development
Tissue factor (Montrer F3 Kits ELISA) plays a hitherto unreported role in the generation of macrophage migratory inhibitory factor by vascular smooth muscle cells in atherosclerosis-prone ApoE (Montrer APOE Kits ELISA)(-/-) mice.
The increased plasmin (Montrer PLG Kits ELISA) generation during the early stages of sepsis could cleave/inactivate TFPI and thus lead to thrombotic complications.
structural features within residues of the 39-loop contribute to the resistance of FIXa (Montrer ETFB Kits ELISA) to inhibition by plasma inhibitors ZPI (Montrer SERPINA10 Kits ELISA) and TFPI.
PAK1 (Montrer PAK1 Kits ELISA) negatively regulates the expression of TFPI and additionally contributes to increased TF activity.
Murine models of combined TFPI and factor VIII deficiency were used to examine the impact of TFPI deficiency on bleeding and clotting in hemophilia
The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis.
The results show that cholesterol crystals induce TFPI and cytokine expression in M2-polarized macrophages through activation of the endoplasmic reticulum stress pathway and that TFPI has a protective effect against TNF-alpha (Montrer TNF Kits ELISA) and IL-6 (Montrer IL6 Kits ELISA) mediated inflammation.
Among high-risk women, the tissue factor pathway inhibitor activity of patients with gestational vascular complications is higher than that in other patients. Hence, these markers could augment a screening strategy.
TFPI single nucleotide polymorphism is associated with venous thromboembolism.
a concentration of tissue factor pathway inhibitor was significantly lower in patients with essential thrombocythemia with JAK2 (Montrer JAK2 Kits ELISA) V617F mutation as compared with patients without the mutation
This review presents a comprehensive understanding of TFPI structure, biochemistry, and cellular expression which is necessary to understand how it modulates bleeding in hemophilia and the physiological impact of therapeutic agents targeting TFPI.
the main finding of the current study is the remarkable elevation in the plasma levels of both total and free TFPI in septic patients at baseline. The levels of both forms of the inhibitor remained elevated throughout the first 24 h with further elevation after enoxaparin administration.
TFPI-1 was a valuable predictor of deep venous thrombosis and tumor metastasis in non-small cell lung cancer patients.
Circulating FVII (Montrer F7 Kits ELISA), FVIIa and TFPI were significantly elevated in women with severe preeclampsia in the absence of comparable changes in plasma TF levels.
HIF-1alpha (Montrer HIF1A Kits ELISA) is involved in the transcriptional regulation of the TFPI gene, and suggests that a hypoxic microenvironment inside a breast tumor may induce a procoagulant state in breast cancer patients.
Upregulated TF expression and increased plasma TF level during reperfusion period, reduced plasma TFPI-1 level during reperfusion period.
This gene encodes a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. The coagulation process initiates with the formation of a factor VIIa-TF complex, which proteolytically activates additional proteases (factors IX and X) and ultimately leads to the formation of a fibrin clot. The product of this gene inhibits the activated factor X and VIIa-TF proteases in an autoregulatory loop. The encoded protein is glycosylated and predominantly found in the vascular endothelium and plasma in both free forms and complexed with plasma lipoproteins. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been confirmed.
extrinsic pathway inhibitor
, lipoprotein-associated coagulation inhibitor
, uncharacterized protein LOC100155068
, tissue factor pathway inhibitor